Editor’s Note: At the highly anticipated ESMO Congress, a wealth of cutting-edge advances will be presented, with uro-oncology standing out as one of the most vibrant and fast-evolving fields. This year, 22 Late-Breaking Abstracts (LBAs) will be showcased, accounting for nearly half of all oral presentations (45 in total) within the uro-oncology track — a testament to the field’s dynamic research momentum and strong clinical relevance.Oncology Frontier – Urology Frontier has carefully selected ten key studies and invited leading Chinese experts to share their insights and expectations. 

Abstract No. LBA2

English Title: Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: The phase 3 KEYNOTE-905 study

Chinese Title: 围手术期使用维恩妥尤单抗联合帕博利珠单抗治疗不适合接受顺铂治疗的肌层浸润性膀胱癌（MIBC）患者：3期KEYNOTE-905研究

Professor Yige Bao

How high can the new perioperative “sandwich” treatment strategy push the pCR rate? Could ADC-based perioperative therapy redefine the paradigm of neoadjuvant treatment for MIBC?

Abstract No. LBA6

English Title: Phase 3 trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)

Chinese Title: [177Lu]Lu-PSMA-617联合ADT+ARPI治疗PSMA阳性转移性激素敏感性前列腺癌患者的3期临床试验（PSMAddition）

Professor Jianming Guo

At this year’s ESMO Congress in Berlin, LBA6 — the global phase III registration study targeting PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC) — will be presented as an oral session. The interim analysis results, released in June, showed that the study had met its primary endpoint, marking a major milestone in RLT research. The upcoming presentation is expected to bring new hope for mHSPC patients and potentially reshape first-line treatment strategies.

Professor Fufu Zheng

The PSMAddition phase III trial to be presented at ESMO will disclose its primary endpoint results. For patients with mHSPC, radioligand therapy (RLT) may offer a new strategy to delay progression to mCRPC and prolong overall survival (OS). These results are expected to address the unmet clinical needs of mHSPC patients and further transform the treatment landscape for advanced prostate cancer.

Abstract No. LBA7

English Title: Disitamab vedotin (DV) plus toripalimab (T) versus chemotherapy (C) in first-line (1L) locally advanced or metastatic urothelial carcinoma (la/mUC) with HER2-expression

Chinese Title: 维迪西妥单抗联合特瑞普利单抗对比化疗一线治疗伴有HER2表达的局部晚期或转移性尿路上皮癌（la/mUC）患者的研究结果

Professor Hao Zeng

The RC48 research program has set a successful model for bringing Chinese uro-oncology innovations to the global stage. May the strongest voice of Chinese uro-oncology continue to resonate across the world.

Professor Jiwei Huang

From the “China-originated” ADC drug to the ‘China-developed’ combination therapy strategy, disitamab vedotin (DV) represents the pioneering spirit of innovation driving China’s uro-oncology field. May this “Chinese solution” illuminate new hope for patients worldwide.

Abstract No. LBA86

English Title: Randomised phase 3 trial of androgen deprivation therapy (ADT) with radiation therapy with or without enzalutamide for high-risk, clinically localised prostate cancer: ENZARAD (ANZUP 1303)

Chinese Title: 雄激素剥夺疗法（ADT）联合放疗（联合或不联合恩扎卢胺）治疗高危、临床局限性前列腺癌的随机3期临床试验：ENZARAD (ANZUP 1303)

Abstract No. LBA87

English Title: Overall survival with enzalutamide in biochemically recurrent prostate cancer

Chinese Title: 恩扎卢胺治疗生化复发性前列腺癌的总生存期

Abstract No. LBA92

English Title: 3-Weekly Docetaxel 75 mg/m² vs 2-Weekly Docetaxel 50 mg/m² in Combination with Darolutamide + ADT in Patients with mHSPC – Results from the Randomised Phase 3 ARASAFE Trial

Chinese Title: 3周一次多西他赛75 mg/m² 对比2周一次多西他赛50 mg/m² 联合达罗他胺+ADT治疗mHSPC患者的疗效比较-随机3期ARASAFE试验结果

Abstract No. LBA95

English Title: Neoadjuvant immunotherapy in locally advanced clear cell renal cell carcinoma at risk for recurrence or distant metastases: the randomized phase II NESCIO trial

Chinese Title: 存在复发或远处转移风险的局部晚期透明细胞肾细胞癌的新辅助免疫治疗：随机II期NESCIO试验

Professor Pei Dong

Neoadjuvant immunotherapy for locally advanced clear cell renal cell carcinoma is not only about tumor downsizing or making unresectable tumors operable — it also aims to prolong disease-free survival and achieve durable long-term outcomes. The upcoming NESCIO trial results are therefore eagerly awaited.

Abstract No. LBA111

English Title: Randomized Comparison of upfront Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Final survival analysis from the BladderPath trial

Chinese Title: 磁共振成像与经尿道切除术用于新诊断膀胱癌分期的随机对照研究：BladderPath试验的最终生存分析

Professor Yige Bao

Is diagnostic TURBT truly irreplaceable? The BladderPath study, which uses MRI-based staging instead of the traditional “TURBT-first” pathway, marks a paradigm shift toward “imaging-first, rapid-decision” clinical management in newly diagnosed bladder cancer. The forthcoming data are expected to further reinforce this transformation in terms of staging accuracy, survival benefit, and cost-effectiveness — laying a stronger foundation for updates to clinical guidelines and practice.

Abstract No. LBA112

English Title: Neoadjuvant gemcitabine intravesical system (TAR-200) + cetrelimab (CET) or CET alone in patients (pts) with muscle-invasive bladder cancer (MIBC): SunRISe-4 (SR-4) primary analysis and biomarker results

Chinese Title: 新辅助吉西他滨膀胱灌注系统（TAR-200）+cetrelimab或单独使用cetrelimab治疗肌层浸润性膀胱癌（MIBC）患者：SunRISe-4（SR-4）初步分析和生物标志物结果

Professor Yige Bao

Can intravesical therapy serve as a neoadjuvant strategy for MIBC? The combination of TAR-200 with cetrelimab — representing a “localized continuous chemotherapy + systemic immunotherapy” model — is emerging as a promising option for cisplatin-ineligible or cisplatin-refusing patients. The upcoming results are expected to further validate its clinical potential and identify the subgroups most likely to benefit.

During the upcoming ESMO Congress, Oncology Frontier – Urology Frontier will continue to feature in-depth and authoritative analyses from study authors and leading international experts. Stay tuned as we follow the pulse of innovation and progress in uro-oncology!

If your favorite study wasn’t listed above, feel free to share in the comments which topics you’re most excited about!